- Question from Jane6: What is the current thinking on LCIS as a precursor to invasive lobular carcinoma? What is the best treatment for LCIS other than vigilance? Is it appropriate for premenopausal women with a weak family history to decline tamoxifen?
- Answers - Carol Kaplan LCIS is still considered a risk factor for development of breast cancer. There is some preliminary research that questions the link between LCIS and invasive lobular carcinoma. However, we have been unable to definitively demonstrate that LCIS has a natural history that leads to invasive cancer directly. Taking tamoxifen is a personal decision, and as long as you feel you have been informed of its particular benefits in breast cancer risk reduction, you can choose close surveillance, including annual MRI and mammography in place of tamoxifen.
The Ask-the-Expert Online Conference called Updates From the 2008 ASCO Annual Meeting featured Generosa Grana, M.D., F.A.C.P. and Carol Kaplan, M.D. answering your questions about the latest research advances on screening, treatment, side effects, and more.
Editor's Note: This conference took place in June 2008.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.